Reactions to vaccination at 15 months post-primary immunization were infrequent and mild. Three volunteers had a slightly painful reaction at the site of injection which lasted less than 48 h. These reactions were similar in nature and frequency to those noted after primary immunization.
Human immunity to Pseudomonas aeruiginosa appears to depend on humoral antibody directed against serospecific lipopolysaccharide (LPS) determinants and toxin A (1, 4, 12) . We have previously described the synthesis of 0 polysaccharide (0-PS)-toxin A conjugate vaccines and their safety and immunogenicity in humans (5) (6) (7) (8) . Given the diverse patient populations at risk to P. aeruginosa infections (2), such vaccines have two potential uses. The first would be to actively vaccinate immunocompetent patients, such as those suffering from burn trauma, who are capable of mounting a protective immune response (1) . Alternatively, plasma could be obtained from healthy immunized donors and be used to produce a hyperimmune globulin (3, 10 Reactions to vaccination at 15 months post-primary immunization were infrequent and mild. Three volunteers had a slightly painful reaction at the site of injection which lasted less than 48 h. These reactions were similar in nature and frequency to those noted after primary immunization.
Anti-LPS IgG antibody engendered by primary immunization was long lived, being significantly (P < 0.05) higher than preimmunization levels after 15 months (Table 1) . Anti-toxin A IgG antibody declined more rapidly over the same period. The booster dose of vaccine administered at 15 months evoked a rapid rise in anti-toxin A IgG antibody. Postboost antibody levels were approximately 10-fold above preimmunization titers (P < 0.01). A total of 50% of the subjects responded with a fourfold or greater rise after immunization, and 90% had titers fourfold or greater above preimmunization levels. In contrast, the booster dose of vaccine elicited only a slight increase in anti-LPS IgG antibody. Even so, 70% of volunteers possessed titers fourfold or greater above base-line levels. Nine months after boosting, IgG antibody levels to toxin A and LPS had declined considerably. Mean anti-toxin A titers were still significantly (P < 0.05) higher than preimmunization levels with five of eight subjects still having titers fourfold or greater above base-line levels. In contrast, anti-LPS antibody levels were not significantly elevated, with only three of eight subjects having titers fourfold or greater above preimmunization levels.
To confirm that the anti-toxin A IgG engendered by boosting was functionally relevant, we tested serum samples for toxin A-neutralizing antibody (Table 1) . Primary immunization evoked a detectable neutralizing antibody response in 80% of the subjects. Fifteen months later, 4 of these 10 subjects still had detectable levels of neutralizing antibody. (9, 11) . These results cannot simply be attributed to a carrier suppression effect (13) , since most volunteers possessed very low anti-toxin A antibody levels before boosting. This would indicate that regulation of a humoral immune response in humans depends, at least in part, on the inherent chemical nature of the antigen.
The findings that immunization with the current O-PStoxin A conjugate vaccine evokes a long-lasting IgG antibody response to both vaccine components and that antitoxin A levels can be increased by a single booster dose demonstrate the versatility of such vaccines. We are currently extending these studies to include toxin A conjugates produced with O-PS derived from additional serotypes of P. aeruginosa LPS.
